Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Official Title: A Phase II Multicenter, Open Label, Non-randomized Study of Neoadjuvant and Adjuvant Treatment With IPH5201 and Durvalumab in Patients With Resectable, Early-Stage (II to III) Non-Small Cell Lung CancEr (MATISSE)

NCT05742607 is registered in ClinicalTrials.gov with Innate Pharma as lead sponsor.

NCT NCT05742607
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05742607 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Official Title: A Phase II Multicenter, Open Label, Non-randomized Study of Neoadjuvant and Adjuvant Treatment With IPH5201 and Durvalumab in Patients With Resectable, Early-Stage (II to III) Non-Small Cell Lung CancEr (MATISSE)
Lead sponsor
Innate Pharma
Phase
Phase 2
Overall status
Recruiting
Start date
June 23, 2023
Completion date
June 30, 2027
Enrollment
70 (estimated)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer